JP2018508491A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018508491A5 JP2018508491A5 JP2017540129A JP2017540129A JP2018508491A5 JP 2018508491 A5 JP2018508491 A5 JP 2018508491A5 JP 2017540129 A JP2017540129 A JP 2017540129A JP 2017540129 A JP2017540129 A JP 2017540129A JP 2018508491 A5 JP2018508491 A5 JP 2018508491A5
- Authority
- JP
- Japan
- Prior art keywords
- oeg
- γglu
- pharmaceutical composition
- human insulin
- desb30 human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical class N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 45
- 239000008194 pharmaceutical composition Substances 0.000 claims description 25
- 102000004877 Insulin Human genes 0.000 claims description 22
- 108090001061 Insulin Proteins 0.000 claims description 22
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 11
- 229920005862 polyol Polymers 0.000 claims description 8
- 150000003077 polyols Chemical class 0.000 claims description 8
- 239000011780 sodium chloride Substances 0.000 claims description 7
- QIQXTHQIDYTFRH-UHFFFAOYSA-N Stearic acid Chemical group CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- 239000000314 lubricant Substances 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 5
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 4
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 4
- 239000000600 sorbitol Substances 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 3
- 239000004026 insulin derivative Substances 0.000 claims description 3
- 239000008117 stearic acid Substances 0.000 claims description 3
- -1 medium chain fatty acid salt Chemical class 0.000 claims description 2
- 101700030984 B29K Proteins 0.000 claims 18
- 102200127556 GNPTAB K4Q Human genes 0.000 claims 10
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 6
- 239000011248 coating agent Substances 0.000 claims 6
- 238000000576 coating method Methods 0.000 claims 6
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 6
- 125000004432 carbon atoms Chemical group C* 0.000 claims 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 2
- 239000000194 fatty acid Substances 0.000 claims 2
- 150000004665 fatty acids Chemical class 0.000 claims 2
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- CTTKODQWVMTOPW-UHFFFAOYSA-N decanoic acid;sodium Chemical compound [Na].CCCCCCCCCC(O)=O CTTKODQWVMTOPW-UHFFFAOYSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000004667 medium chain fatty acids Chemical class 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims 1
- 229910052708 sodium Inorganic materials 0.000 claims 1
- 239000011734 sodium Substances 0.000 claims 1
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-M stearate Chemical compound CCCCCCCCCCCCCCCCCC([O-])=O QIQXTHQIDYTFRH-UHFFFAOYSA-M 0.000 description 3
- FBPFZTCFMRRESA-KAZBKCHUSA-N D-Mannitol Natural products OC[C@@H](O)[C@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KAZBKCHUSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Stearin Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2015/051813 WO2016119854A1 (en) | 2015-01-29 | 2015-01-29 | Pharmaceutical composition for oral insulin administration comprising a tablet core and a polyvinyl alcohol coating |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020082000A Division JP2020117542A (ja) | 2020-05-07 | 2020-05-07 | 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2018508491A JP2018508491A (ja) | 2018-03-29 |
JP2018508491A5 true JP2018508491A5 (es) | 2019-10-03 |
JP6737793B2 JP6737793B2 (ja) | 2020-08-12 |
Family
ID=52462305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017540129A Expired - Fee Related JP6737793B2 (ja) | 2015-01-29 | 2015-01-29 | 錠剤コアとポリビニルアルコールコーティングとを含む経口インスリン投与のための医薬組成物 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20180000742A1 (es) |
EP (1) | EP3250225A1 (es) |
JP (1) | JP6737793B2 (es) |
CN (1) | CN107206059A (es) |
WO (1) | WO2016119854A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3668892A1 (en) | 2017-08-17 | 2020-06-24 | Novo Nordisk A/S | Novel acylated insulin analogues and uses thereof |
EP3894391A1 (en) | 2018-12-11 | 2021-10-20 | Sanofi | Peptide binder |
WO2021029467A1 (en) * | 2019-08-14 | 2021-02-18 | Sam Chun Dang Pharm. Co., Ltd. | A solid dosage form for orally administration |
WO2023012263A1 (en) | 2021-08-04 | 2023-02-09 | Novo Nordisk A/S | Solid oral peptide formulations |
WO2023166179A1 (en) | 2022-03-03 | 2023-09-07 | Cyprumed Gmbh | Improved oral pharmaceutical formulations of therapeutic peptides and proteins |
WO2024110614A1 (en) | 2022-11-25 | 2024-05-30 | Novo Nordisk A/S | Oral administration of peptide therapeutics, such as glp-1 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3935326A (en) * | 1967-06-28 | 1976-01-27 | Boehringer Mannheim G.M.B.H. | Process for coating tablets with aqueous resin dispersions |
GB9414045D0 (en) * | 1994-07-12 | 1994-08-31 | Berwind Pharma Service | Moisture barrier film coating composition, method, and coated form |
SI21402A (sl) * | 2003-02-12 | 2004-08-31 | LEK farmacevtska dru�ba d.d. | Obloženi delci in farmacevtske oblike |
CN1863510A (zh) * | 2003-08-13 | 2006-11-15 | 比奥孔有限公司 | 用于治疗剂的微-粒子脂肪酸盐固体剂量制剂 |
RU2428178C2 (ru) * | 2004-06-07 | 2011-09-10 | Вайет | Сахарные покрытия и способы их применения |
US7605123B2 (en) * | 2004-07-19 | 2009-10-20 | Biocon Ltd. | Fatty acid formulations for oral delivery of proteins and peptides, and uses thereof |
BRPI0710503A2 (pt) * | 2006-04-07 | 2011-08-16 | Merrion Res Iii Ltd | uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral |
KR101729986B1 (ko) * | 2006-09-22 | 2017-04-25 | 노보 노르디스크 에이/에스 | 프로테아제 내성 인슐린 유사체 |
JP5868594B2 (ja) * | 2007-10-16 | 2016-02-24 | バイオコン・リミテッドBiocon Limited | 経口投与可能な固形医薬組成物及びそのプロセス |
DK2910570T3 (en) * | 2008-03-18 | 2017-01-30 | Novo Nordisk As | Protease-stabilized acylated insulin analogues. |
US20110142889A1 (en) * | 2009-12-16 | 2011-06-16 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
WO2011084618A2 (en) * | 2009-12-16 | 2011-07-14 | Nod Pharmaceuticals, Inc. | Compositions and methods for oral drug delivery |
CN102335431B (zh) * | 2010-07-14 | 2015-08-26 | 上海蓝心医药科技有限公司 | 一种给药组合物及其制备和使用方法 |
CN102985440B (zh) * | 2010-06-23 | 2016-10-26 | 诺沃-诺迪斯克有限公司 | 包含额外的二硫键的胰岛素衍生物 |
JP2015502971A (ja) * | 2011-12-21 | 2015-01-29 | ノヴォ ノルディスク アー/エス | N末端修飾インスリン誘導体 |
EP3003267A1 (en) * | 2013-05-30 | 2016-04-13 | Novo Nordisk A/S | Novel oral pharmaceutical composition for treatment of diabetes |
-
2015
- 2015-01-29 CN CN201580074826.5A patent/CN107206059A/zh not_active Withdrawn
- 2015-01-29 EP EP15703036.2A patent/EP3250225A1/en not_active Withdrawn
- 2015-01-29 WO PCT/EP2015/051813 patent/WO2016119854A1/en active Application Filing
- 2015-01-29 US US15/546,299 patent/US20180000742A1/en not_active Abandoned
- 2015-01-29 JP JP2017540129A patent/JP6737793B2/ja not_active Expired - Fee Related
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2018508491A5 (es) | ||
HRP20200753T1 (hr) | Farmaceutske formulacije koje sadrže dapagliflozin propilen glikol hidrat | |
RU2016151697A (ru) | Расправляемая удерживаемая в желудке лекарственная форма | |
JP2008501025A5 (es) | ||
AR075735A1 (es) | Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso | |
HRP20231613T1 (hr) | Pripravci koji sadrže sredstvo za unošenje i njihova priprava | |
SI2760821T1 (en) | A salt salt of an anti-inflammatory substituted cyclobutenedione compound | |
JP2013100317A5 (es) | ||
JP2015515459A5 (es) | ||
JP2011079859A5 (es) | ||
JP2015510916A5 (es) | ||
JP2015038135A5 (es) | ||
IL195732A (en) | Pharmaceutical compounds containing passoterodine, their use and method for their preparation | |
JP2018184458A5 (es) | ||
JP2019516739A5 (es) | ||
AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
JP2013522326A5 (es) | ||
JP2016510326A5 (es) | ||
ES2957495T3 (es) | Formulaciones de comprimidos de liberación modificada que contienen inhibidores de fosfodiesterasa | |
PE20130657A1 (es) | Composiciones farmaceuticas que comprenden hidromorfona y naloxona | |
WO2020138791A3 (ko) | 토파시티닙 또는 그의 약제학적으로 허용되는 염을 함유한 서방성 제제 및 그의 제조방법 | |
AR100977A1 (es) | Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación | |
KR102055859B1 (ko) | 아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합 | |
EP3513811A1 (en) | Delayed release dosage forms comprising dimethyl fumarate | |
RU2018137590A (ru) | Фармацевтические композиции для производного n-пропаргиламина |